Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

NCT04941716 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fred Hutchinson Cancer Center

Collaborators